Finnish drugmaker Orion's Q2 profit, sales beat forecasts

Finnish drugmaker Orion on Friday reported better-than-expected April-June profits and sales, boosted by a milestone payments for its prostate cancer drug.

July 17 (Reuters) - Finnish drugmaker Orion on Friday reported better-than-expected April-June profits and sales, boosted by a milestone payments for its prostate cancer drug.

Orion's operating profit rose 85% from a year earlier to 96.4 million euros ($110 million) on sales up 16% to 292.5 million euros, both well ahead of analysts expectations Refinitiv Eikon data showed.

Last week Orion said it expects operating profit this year to be higher than in 2019, after previously forecasting a flat outcome.

($1 = 0.8763 euros) (Reporting by Tarmo Virki in Tallinn; editing by Jason Neely) ((tarmo.virki@thomsonreuters.com; +372 564 4562 ;)) Keywords: ORION RESULTS/ (URGENT)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More